2022³â ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-03±³À°ÀÏÀÚ : 2022-09-03
±³À°Àå¼Ò : ÀüÁÖ ÆòÈÀÇÀü´ç À¯Ç×°ËȦ, ¼¼¹Ì³ª½Ç
±³À°ÁÖÁ¦ :
2022³â ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ (ÀÌ»çÀåÁ¦)
´ã´çÀÚ : »ç¹«±¹
¿¬¶ôó : 070-4888-5731
À̸ÞÀÏ :
ksbtp.svc@gmail.com ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
Àü¶óºÏµµ±³À°½Ã°£ : 12 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í »çÀüµî·Ï-Àü¹®ÀÇ 40,000¿ø/±ºÀü¹®ÀÇ,°øº¸ÀÇ,Àü°øÀÇ 20,000¿ø/°£È£»ç,ÀÓ»ó½É¸®»ç,»çȸº¹Áö»ç 20,000¿ø/Æò»ýȸ¿ø-¸éÁ¦ ÇöÀåµî·Ï-¾øÀ½
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 09:25~09:50 Depression and anxiety during COVID-19 Àå¿ÁÁø(±¹¸³ºÎ°îº´¿ø)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 09:50~10:15 The potential impact of COVID-19 on psychosis õÀºÁø(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 10:15~10:40 The impact of the COVID-19 pandemic on the mental health of Koreans Á¤¼º¿ø(°è¸íÀÇ´ë)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 10:40~10:50 ÁúÀÇ ¹× Åä·Ð ()
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 11:00~11:25 Psychotic symptoms in dementia ¼ÛÁ¦Çå(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 11:25~11:50 Mood and affective symptoms in dementia ÀÓÀº¼º(È¿»ç¶ûº´¿ø)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 11:50~12:15 Sleep disturbance in dementia ¹æ¿µ·Õ(¿ï»êÀÇ´ë)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 12:15~12:25 ÁúÀÇ ¹× Åä·Ð ()
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 12:30~13:05 Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia ±è¼º¿Ï(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 13:05~13:40 Improving Outcomes of Bipolar Disorder with Long-acting-Injectable Antipsychotics Treatment: Impact on Patients and Careers Àå¼¼Çå(±è¿ø¹¬±â³äºÀ»ýº´¿ø)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 13:40~14:05 Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality À̽ÂÀç(°æºÏÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 14:05~14:30 Effects of drug therapy as an early intervention in psychotic disorders À̺´´ë(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 14:30~14:55 Mindlink: A stigma-free youth-friendly community-based early-intervention centre in Korea ±è¼º¿Ï(Àü³²ÀÇ´ë)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 14:55~15:05 ÁúÀÇ ¹× Åä·Ð ()
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 15:15~15:40 Glucose Metabolism and Obesity in Bipolar Disorder ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 15:40~16:05 Molecular Biological Association between Bipolar Disorder and Obesity ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 16:05~16:30 Development of a new treatment target for bipolar disorder in the mechanism of action of antidiabetic drugs °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç À¯Ç×°ËȦ 16:30~16:40 ÁúÀÇ ¹× Åä·Ð ()
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 09:25~09:50 The role of dopamine in the schizophrenia and mood disorder °Å¿í(À»ÁöÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 09:50~10:15 Serotonergic and noradrenergic systems in depression and anxiety disorder ÀÌ»ó¿ø(°æºÏÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 10:15~10:40 Update of other neurotransmitters: glutamate, GABA, acetylcholine Àü¼Ò¿¬(Ãæ³²ÀÇ´ë)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 10:40~10:50 ÁúÀÇ ¹× Åä·Ð ()
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 11:00~11:25 The general medical conditions causing psychotic symptom ±è°æ¿ø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 11:25~11:50 Conditions that affect cognitive function Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 11:50~12:15 The effects of acute and chronic stress ¼È±Ô(ºÎ»êÀÇ´ë)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 12:15~12:25 ÁúÀÇ ¹× Åä·Ð ()
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 13:40~14:05 Schizoaffective disorder À±¼®È£(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 14:05~14:30 Schizophrenia and OCD À±ÇüÁØ(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 14:30~14:55 Schzophrenia and autism spectrum disorder ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 14:55~15:05 ÁúÀÇ ¹× Åä·Ð ()
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 15:15~15:40 COVID-19 and psychoimmunology ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 15:40~16:05 Safety of psychiatric medications in COVID-19 ÀÌÁ¤¾È(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 16:05~16:30 The effectiveness of telepsychiatry È«Á¤¿Ï(Àͻ꺴¿ø)
Åä·Ð 09-03 ÀüÁÖÆòÈÀÇÀü´ç ¼¼¹Ì³ª½Ç 16:30~16:40 ÁúÀÇ ¹× Åä·Ð ()